Beam Therapeutics (NASDAQ:BEAM) Rating Increased to Overweight at Cantor Fitzgerald
Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.
Le Lézard2d
AIRNA Appoints Matthew Hawryluk as Chief Business Officer
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases, today announced the appointment of Matthew Hawryluk, Ph.D., MBA, as Chief ...
Apple downgraded, Rivian initiated: Wall Street's top analyst calls
Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after the ...
Hosted on MSN5d
Intellia Stock Dips After Morgan Stanley Downgrade, Retail Sentiment Weakens
Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...
Twilio, Qorvo upgraded: Wall Street's top analyst calls
Goldman Sachs upgraded Twilio (TWLO) to Buy from Neutral with a price target of $185, up from $77, after the company's ...
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $11, down from $56. The firm now ...
What is Leerink Partnrs’ Forecast for BEAM FY2024 Earnings?
Equities research analysts at Leerink Partnrs boosted their FY2024 earnings estimates for Beam Therapeutics in a research note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst M ...